

## H. Lundbeck A/S

Ottiliavej 9  
DK-2500 Valby, Copenhagen  
CVR number: 56759913  
LEI code: 5493006R4KC2OI5D3470

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail investor@lundbeck.com  
www.lundbeck.com



## Corporate Release

### Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

**Valby, Denmark, 7 February 2024** – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1.	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Johan Luthman	
2.	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President, Research & Development	
b)	Initial notification/Amendment	Initial notification	
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2OI5D3470	
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	A-shares: DK0061804697 B-shares: DK0061804770	
b)	Nature of the transaction	Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0	A-shares: 6,737 B-shares: 26,945
d)	Aggregated information - Aggregated volume - Price		
e)	Date of the transaction	2024-02-07	
f)	Place of the transaction	NASDAQ Copenhagen XCSE	

1.	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Jacob Tolstrup	
2.	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President, Commercial Operations	
b)	Initial notification/Amendment	Initial notification	
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2OI5D3470	
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	A-shares: DK0061804697 B-shares: DK0061804770	
b)	Nature of the transaction	Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0	A-shares: 6,396 B-shares: 25,583
d)	Aggregated information - Aggregated volume - Price		
e)	Date of the transaction	2024-02-07	
f)	Place of the transaction	NASDAQ Copenhagen XCSE	

1.	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Keld Flintholm Jørgensen
2.	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, Corporate Strategy & Business Development
b)	Initial notification/Amendment	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	H. Lundbeck A/S
b)	LEI code	5493006R4KC2OI5D3470
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument  Identification code	Shares  A-shares: DK0061804697 B-shares: DK0061804770
b)	Nature of the transaction	Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)
c)	Price(s) and volume(s)	Price(s)      Volume(s)
		DKK 0      A-shares: 4,913 B-shares: 19,649
d)	Aggregated information - Aggregated volume - Price	
e)	Date of the transaction	2024-02-07
f)	Place of the transaction	NASDAQ Copenhagen XCSE

1.	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Lars Bang	
2.	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President, Product Development & Supply	
b)	Initial notification/Amendment	Initial notification	
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2OI5D3470	
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	A-shares: DK0061804697 B-shares: DK0061804770	
b)	Nature of the transaction	Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0	A-shares: 6,626 B-shares: 26,504
d)	Aggregated information - Aggregated volume - Price		
e)	Date of the transaction	2024-02-07	
f)	Place of the transaction	NASDAQ Copenhagen XCSE	



Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.

### Lundbeck contacts

Investors:

Palle Holm Olesen

Vice President, Investor Relations

PALO@lundbeck.com

+45 30 83 24 26

Media:

Thomas Mikkel Mortensen

Media Relations Lead, Corporate Communication

THMR@lundbeck.com

+45 30 83 30 24

Sophia Nørskov Bech

Senior Manager, Investor Relations

SONQ@lundbeck.com

+45 30 83 24 60

### About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.

For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com) and connect with us via LinkedIn.